GTI-2501 Lorus Therapeutics

Current Opinion in Investigational Drugs

Volumn 2, Issue 10, 2001, Pages 1467-1470

  Tu, G C ^a   Tu, X ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; GTI 2501; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER INHIBITION; CANCER MODEL; CHEMICAL MODIFICATION; CLINICAL TRIAL; DOSE CALCULATION; DOSE RESPONSE; DRUG BINDING; DRUG CONTRAINDICATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; IN VIVO STUDY; LYMPHOMA; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL; REVIEW; SIDE EFFECT; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; HUMANS; LYMPHOMA; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034782427     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. In vivo stability, disposition and metabolism of a hybrid oligonucleotide phosphorothioate in rats
2. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey
3. Effect of different chemically modified oligodeoxynucleotides on immune stimulation
4. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice
5. Effects of synthetic oligonucleotides on human complement and coagulation
6. Antisense therapeutic
7. Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: Initial results of a phase I trial
8. Lorus Therapeutics announces anticancer drug GTI 2501 demonstrates total regression of cancer in animal models
9. Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A); Comparison with other delivery routes
10. Lorus Therapeutics receives issued United States patent for invention of key anticancer drugs
11. Lorus Therapeutics' lead anti-cancer drugs reduce tumor growth in mouse models with human prostate cancer cells
12. Lorus Therapeutics allowed US patent to specifically protect GTI-2501; 266 excellent preclinical results of GTI-2501, patent protection allowed for key anticancer drug
13. AVI BioPharma and Lorus Therapeutics form dynamic antisense research collaboration: Companies team up to develop novel drug treatments for cancer and infectious diseases
14. Lorus Therapeutics reports year-end results
15. Successful toxicology results allows Lorus Theapeutics to advance GTI-2501 to clinical trial - GTI-2501 shows high levels of safety in animal studies
16. Lorus Therapeutics appoints interim chairman of the board; former president of Connaught Laboratories named to the post
17. Lorus Therapeutics presents at the 10th International Congress on anticancer treatment: Company to discuss anticancer products at International Conference in France
18. Lorus Therapeutics granted FDA approval to proceed with a clinical trial for its anticancer drug, GTI-2501
19. Lorus Therapeutics treats first patient in phase I clinical trial for GTI-2501 - The company's third anti-cancer drug begins clinical trial program
20. Antisense oligonucleotides: Towards Clinical Trials
21. How to design an antisense oligonucleotide experiment: A consensus approach
22. Inhibition of coagulation by a phosphorothioate oligonucleotide
23. CEO Interview: Jim Wright - Lorus Therapeutics Inc (LORFF)
24. Specific suppression of human tumor necrosis factor-alpha by antisense oligonucleotides